Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Diversity and Inclusion Within Datasets in Heart Failure
2
Zitationen
22
Autoren
2025
Jahr
Abstract
BACKGROUND: Heart failure (HF) is a life-threatening disease affecting 64 million people worldwide. Artificial intelligence (AI) technologies are being developed for use in HF to support early diagnosis and stratification of treatment. The performance characteristics of AI technologies are influenced by whether the data used during the AI lifecycle reflects the populations for which the AI is used. OBJECTIVES: The aim of the study was to identify and characterize datasets used across the lifecycle of AI technologies for HF, focusing on data diversity and inclusivity. METHODS: MEDLINE and Embase were systematically searched from January 1, 2012, until August 30, 2022, to identify articles relating to the development of AI in HF. Articles were independently screened by 2 reviewers to identify datasets. Dataset documentation was analyzed with a focus on accessibility, geographical origin, relevant metadata reporting, and dataset composition. RESULTS: The 72 datasets identified represented 23 countries and over 2 million individuals. In total, 62 (86%) datasets reported "age," 61 (85%) reported sex or gender, 21 (29%) reported race and/or ethnicity, and 8 (11%) reported socioeconomic status. In the 21 datasets that reported race and/or ethnicity, 89% of individuals represented were reported within the "White" or "Caucasian" category. Only 20 (28%) datasets were fully accessible. CONCLUSIONS: Reporting of sex, gender, and socioeconomic status in HF datasets is inconsistent. There is a need to generate datasets that are transparently reported and accessible. Although collecting and reporting demographic attributes is complex and needs to be undertaken with appropriate safeguards, it is also an essential step toward building equitable AI-based health technologies.
Ähnliche Arbeiten
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.
2021 · 19.544 Zit.
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
2021 · 12.680 Zit.
2013 ACCF/AHA Guideline for the Management of Heart Failure
2013 · 12.619 Zit.
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 · 11.735 Zit.
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
2002 · 11.655 Zit.
Autoren
- Elinor Laws
- Maria Charalambides
- Sonam Vadera
- Eva Keller
- Joseph Alderman
- Breanna Blackboro
- Henry David Jeffry Hogg
- Thomas S. Salisbury
- Joanne Palmer
- Melanie Calvert
- Maxine Mackintosh
- Rubeta Matin
- Elizabeth Sapey
- Johan Ordish
- Melissa D. McCradden
- Bilal A. Mateen
- Jacqui Gath
- Ade Adebajo
- Stephanie Kuku
- William Bradlow
- Alastair K. Denniston
- Xiaoxuan Liu
Institutionen
- University Hospitals Birmingham NHS Foundation Trust(GB)
- University of Southampton(GB)
- University Hospitals of Leicester NHS Trust(GB)
- University College London(GB)
- University of Birmingham(GB)
- South Tyneside and Sunderland NHS Foundation Trust(GB)
- NIHR Birmingham Biomedical Research Centre(GB)
- The Alan Turing Institute(GB)
- Oxford University Hospitals NHS Trust(GB)
- Hospital for Sick Children(CA)
- The Patients Association(GB)
- University of Sheffield(GB)